Targeted Therapy (Investigational)
44 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Investigational) (10)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
BGB-16673 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
BGB-16673 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
CFT7455 (Cereblon Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
CFT7455 (Cereblon Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Elenestinib |
Next-Generation KIT D816V Inhibitor | Hematologic | ||
|
Molecule
Elenestinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Next-Generation KIT D816V Inhibitor |
||||
Emavusertib |
IRAK4 Kinase Inhibitor | Hematologic | ||
|
Molecule
Emavusertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
IRAK4 Kinase Inhibitor |
||||
Guadecitabine |
Hypomethylating / Investigational Agent | Hematologic (MDS/AML) | ||
|
Molecule
Guadecitabine
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MDS/AML)
Drug Class / Mechanism
Hypomethylating / Investigational Agent |
||||
Ianalumab |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
Ianalumab
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Nemtabrutinib |
Reversible (Non-Covalent) BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Nemtabrutinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Reversible (Non-Covalent) BTK Inhibitor |
||||
NX-2127 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
NX-2127 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
NX-5948 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
NX-5948 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Pelabresib |
BET Bromodomain Inhibitor | Hematologic (MPN) | ||
|
Molecule
Pelabresib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
BET Bromodomain Inhibitor |
||||
BGB-16673 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
CFT7455 (Cereblon Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
ElenestinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Next-Generation KIT D816V Inhibitor |
|
EmavusertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
IRAK4 Kinase Inhibitor |
|
GuadecitabineTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MDS/AML)
Drug Class / Mechanism
Hypomethylating / Investigational Agent |
|
IanalumabTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
NemtabrutinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Reversible (Non-Covalent) BTK Inhibitor |
|
NX-2127 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
NX-5948 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
PelabresibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
BET Bromodomain Inhibitor |
|